volixibat

an inhibitor of apical sodium-dependent bile acid transporter

Also Known As:

LUM002; SHP626; beta-D-glucopyranosylamine, N-(((3-((3S,4R,5R)-3-butyl-7-(dimethylamino)-3-ethyl-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenyl)amino)carbonyl)-3-O-(phenylmethyl)-, 6-(hydrogen sulfate)

Networked: 5 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Palmer, Melissa: 5 articles (01/2020 - 01/2018)
2.	Bliss, Caleb: 2 articles (02/2018 - 01/2018)
3.	Jennings, Lee: 2 articles (02/2018 - 01/2018)
4.	Silberg, Debra G: 2 articles (02/2018 - 01/2018)
5.	Aithal, Guruprasad P: 1 article (01/2020)
6.	Freilich, Bradley: 1 article (01/2020)
7.	Hassanein, Tarek: 1 article (01/2020)
8.	Herring, Robert: 1 article (01/2020)
9.	Kayali, Zeid: 1 article (01/2020)
10.	Lee, Hak-Myung: 1 article (01/2020)

Related Diseases

1.	Fatty Liver 01/01/2020 - "These results show that volixibat is not an effective treatment for people with fatty liver disease. "
2.	Alcoholic Fatty Liver 01/01/2020 - "Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study." 01/01/2018 - "A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis." 01/01/2019 - "Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice." 01/01/2020 - "Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT) that has been hypothesized to improve non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepatic bile acid production. "
3.	Non-alcoholic Fatty Liver Disease 01/01/2020 - "This study investigated whether volixibat could reduce the amount of fat in the liver and reduce liver injury in adults with an advanced form of non-alcoholic fatty liver disease. " 01/01/2019 - "Non-alcoholic fatty liver disease activity score (NAS) was significantly lower in volixibat-treated mice than in the HFD controls. " 02/01/2018 - "Volixibat is a potent inhibitor of the apical sodium-dependent bile acid transporter in development for the treatment of nonalcoholic steatohepatitis. "
4.	Overweight 01/01/2018 - "Overweight and obese adults were randomised 3:1 to double-blind volixibat or placebo, respectively, for 12 days. " 01/01/2018 - "A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis." 01/01/2018 - "This study indicates that maximal inhibition of bile acid reabsorption, as assessed by FBA excretion, occurs at volixibat doses of ≥20 mg/day in obese and overweight adults, without appreciable change in gastrointestinal tolerability. "
5.	Fibrosis (Cirrhosis) 01/01/2020 - "In this double-blind, phase II dose-finding study, adults with ≥5% steatosis and NASH without cirrhosis (N = 197) were randomized to receive volixibat (5, 10 or 20 mg) or placebo once daily for 48 weeks. "

Related Drugs and Biologics

1.	volixibat
2.	sodium-bile acid cotransporter
3.	Bile Acids and Salts (Bile Acids)
4.	Triglycerides (Triacylglycerol)
5.	Cholesterol Esters (Cholesteryl Esters)
6.	nas